The businesses within the BBI Group offer a portfolio of products and services that are delivered to the diagnostic and life science industries globally.
We pride ourselves on offering regulatory compliant products and services to all of our partners, whatever the requirement, with a commitment to the needs of each individual project and the onward success of our customers.
BBI Solutions is a leading expert in immunoassay development and manufacturing services and provides an extensive portfolio of products and technologies to the global diagnostic market. Read about our products, services news and more here
Novarum™ DX technology transforms a smartphone into a diagnostic test reader, empowering users to read and share the results of rapid tests from the point of care.
Our pioneering technology can be used by anyone, anywhere, with minimal training: connecting patients and doctors, field workers, lab researchers and primary care clinicians to specialist practices as part of a mobile eco-system. Read about how this technology is revolutionising point of care testing here
|Maine Biotechnology Services
In 2017 BBI Group acquired Maine Biotechnology Services (MBS) adding antibody development to its capabilities.
Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs. Learn more about our enhanced antibody offering here
BBI Group were delighted to annouce the acquisition of German based DIARECT AG in June 2020. The acquisition of DIARECT and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio. To find out more about the DIARECT offering please visit here